Celanese Corporation, a global chemical and specialty materials company, has expanded its Florence, KY research and development center with the addition of a pharmaceutical drug delivery feasibility lab. The new feasibility lab will drive new development for long-acting controlled release drug delivery. This represents a significant investment and commitment to the pharmaceutical segment of Celanese’s engineered materials business. The feasibility lab expands pharmaceutical companies’ access to highly customized materials and service solutions.
 
The new Florence pharmaceutical feasibility lab enables Celanese to accelerate customers’ development projects for long-acting delivery of small molecules, biologics and RNA. Services include: material characterization; injection molding, hot-melt extrusion, and other prototyping capabilities; monolithic or multi-layer drug-loaded prototypes; in vitro characterization and drug release studies; and tooling design and development.
 
“When Celanese works with pharmaceutical customers, we first seek to understand their design challenges and identify factors that are critical to quality,” said Jeff Haley, senior manager and product specialist, pharmaceutical development, Celanese. “We then assemble the right team of experts, select the right tool set, and develop a program plan to help solve their materials challenges. Technical or materials requirements vary by customer, and Celanese is here to offer targeted solutions to ensure our customers can quickly bring to market a successful product that has a meaningful impact on patient health and quality of life.”